Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

The ulixertinib program is open to adult and adolescent cancer patients who have exhausted other treatment options and who have MAPK pathway alterations.

Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.

The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.

The company will seek FDA approval in advanced systemic mastocytosis, a disorder that can turn into cancer in 7 percent of children and 30 percent of adults.

The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Oct
29

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.